Cancer Treatment in China for Indonesian Patients: What Families Need to Know
Indonesian patients with blood cancers, relapsed leukaemia, or complex haematological conditions face a specific challenge: several treatment options that are now standard at high-volume oncology centres elsewhere — including CAR-T cell therapy and advanced haploidentical transplant — are not yet available in Indonesia. For families in this situation, China offers a concrete clinical alternative. This article explains when that option is relevant, and how the process works practically from Indonesia.
This article addresses:
- What cancer treatments are not currently available in Indonesia
- The four clinical situations where China specifically adds value for Indonesian patients
- Practical logistics: flights from Jakarta, visa, halal requirements, BPJS, and financial transfers
- How the coordination process works — starting remotely, without travel
- Frequently asked questions from Indonesian families
What Is — and Is Not — Currently Available in Indonesia
Indonesia has capable oncology facilities. The National Cancer Centre (Rumah Sakit Kanker “Dharmais”) in Jakarta, major private institutions such as MRCCC Siloam Semanggi, and university hospitals offer standard haematology treatment including chemotherapy and some forms of bone marrow transplantation. For many patients, treatment in Indonesia is appropriate and sufficient.
The limitation is not in routine care — it is in specific advanced treatments that require both regulatory approval and sustained institutional volume to deliver safely.
CAR-T cell therapy
No CAR-T products have been approved by BPOM (the Indonesian Food and Drug Authority) or implemented at Indonesian hospitals as of the time of this writing. Patients with relapsed or refractory B-cell leukaemia, lymphoma, or multiple myeloma who require CAR-T must travel abroad. China, Singapore, and the United States are the primary destinations.
Haploidentical transplant at volume
Some Indonesian hospitals perform allogeneic bone marrow transplantation, but the annual volume of haploidentical (half-matched) transplant cases is very limited. For patients without a matched sibling donor — common in families with one or two children — the haploidentical option may not be readily available locally with the same depth of experience that high-volume specialist centres can offer.
Matched unrelated donor availability
Indonesian patients searching for a matched unrelated donor through international registries face a specific structural disadvantage: DKMS, NMDP/Be The Match, and similar registries are predominantly composed of donors from European backgrounds. For patients of Indonesian or broader Southeast Asian heritage, the probability of finding a fully matched (10/10 HLA) unrelated donor is considerably lower than for patients from European backgrounds — sometimes substantially so.
When China Specifically Adds Value for Indonesian Patients
This article does not suggest that all Indonesian cancer patients should seek treatment abroad. Standard treatment — chemotherapy, surgery, radiotherapy, targeted therapy — is available and appropriate in Indonesia for the majority of patients. The clinical situations where China adds specific value are narrower and more defined.
CAR-T therapy for relapsed or refractory blood cancers
China has multiple NMPA-approved CAR-T products and active programmes for blood cancers including B-cell ALL, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, multiple myeloma, and others. These products are available to international patients at major haematology centres in Beijing and Shanghai. For Indonesian patients who have relapsed after standard chemotherapy and need CAR-T, China is currently one of the most accessible destinations — combining approved products with significantly lower costs than equivalent treatment in the United States or Western Europe.
Haploidentical transplant when no matched donor is available
China has accumulated the world's largest published clinical experience with haploidentical transplant through the Beijing Protocol, developed at Peking University Institute of Haematology. For Indonesian patients whose bone marrow donor registry search has failed — or who do not have a matched sibling donor — a haploidentical parent donor evaluation is available through Chinese specialist centres. Crucially, this is not a last resort: haploidentical donors now account for 56% of all paediatric transplants nationally in China, and published outcomes for many indications are comparable to matched unrelated donor transplant. See the CCBMTR 2017–2024 registry analysis for the full dataset.
Complex paediatric blood disorders
For Indonesian children with rare inherited blood disorders — aplastic anaemia, thalassaemia major, Fanconi anaemia, or paediatric leukaemia requiring transplant — Chinese paediatric haematology centres offer both the procedure volume and the institutional experience that is difficult to access locally. Indonesia has a high prevalence of thalassaemia; Chinese centres have published among the most extensive outcomes data for thalassaemia transplantation using haploidentical donors, including in patients with prior complications.
Structured second opinion before major treatment decisions
For Indonesian patients who have been diagnosed with a complex cancer and want an independent specialist review before committing to a treatment plan — or whose local oncology team has recommended transplant, CAR-T, or another major intervention — an online MDT consultation with Chinese specialists can be arranged without travel. This review produces a written assessment that can be shared with the patient's local team and used to inform a final decision.
For Indonesian families navigating a donor shortage specifically, the haploidentical transplant resource hub provides detailed information on the Beijing Protocol, parent donor evaluation, and published outcomes data.
Indonesian family facing relapse, donor shortage, or a difficult treatment decision?
A structured case review with Chinese haematology and oncology specialists can assess whether treatment in China is clinically relevant — before any travel decision is made. No commitment required.
Request a case reviewPractical Information for Indonesian Families
Indonesian patients and families consistently ask the same practical questions before exploring treatment in China. The following addresses the most important ones directly.
Flights and travel time
Jakarta and Bali are connected to Beijing and Shanghai via several carriers, typically with one transit stop — through Kuala Lumpur, Singapore, Hong Kong, or Guangzhou. Total travel time is generally seven to ten hours depending on the routing and connection. Families should plan for extended stays: CAR-T therapy involves two separate trips totalling two to four months; bone marrow transplant requires a continuous in-country stay of approximately three to five months including post-transplant monitoring.
Visa and entry requirements
Entry requirements for Indonesian citizens visiting China may change. We recommend checking current requirements directly with the Chinese Embassy or Consulate in Jakarta before making travel plans. For extended treatment stays that exceed a standard tourist visa duration, the coordinating hospital's international patient team can typically advise on available visa categories for medical treatment purposes.
BPJS Kesehatan and health insurance
BPJS Kesehatan, Indonesia's national health insurance programme, does not cover medical treatment received outside Indonesia. Private Indonesian health insurance policies vary — some may include limited overseas coverage for emergency or specialist treatment, while many do not. Indonesian families should request written confirmation of any overseas coverage from their insurer before making financial commitments. In most cases, treatment in China will need to be planned as an out-of-pocket cost.
Dietary and religious requirements
Indonesia has the world's largest Muslim-majority population, and halal dietary requirements are a practical priority for most Indonesian families. Major Chinese hospitals with established international patient services — particularly in Beijing and Shanghai — can typically arrange halal-certified food for patients in international patient wards, though this should be confirmed in advance with the hospital's international patient coordination team. Prayer facilities and the availability of private space for prayer vary by institution and should be discussed before arrival.
Financial transfers from Indonesia
Moving funds from Indonesia to China requires international wire transfers, which are subject to processing times and may involve transaction limits depending on the bank and transfer amount. Indonesian families should plan the transfer logistics in advance: treatment costs in China are typically settled according to a structured schedule — often partially in advance — and delays in fund availability can create complications. Consulting an Indonesian bank with international transfer experience before departure is recommended.
Language and Communication
Bahasa Indonesia and Mandarin are not mutually intelligible, and real-time interpretation between Indonesian and Chinese during medical consultations is not routinely available at most Chinese hospitals. At hospitals with established international patient services, coordination is typically managed in English — which serves as the shared communication language between Indonesian families and Chinese specialist teams.
Indonesian families who have limited English proficiency should identify a bilingual family member or advocate — fluent in both Indonesian and English — who can participate fully in communications throughout the process. This includes records preparation, medical consultations, discharge planning, and post-treatment follow-up coordination. The quality of communication is directly relevant to the safety and effectiveness of the care experience.
How the Process Works: Starting Without Travel
The process for an Indonesian patient exploring treatment at a Chinese haematology or oncology centre does not begin with a flight booking. It begins with a clinical records review.
Step 1: Records compilation
Existing medical records from the treating team in Indonesia — including pathology reports, imaging (CT, PET-CT, MRI), bone marrow biopsy results, treatment history, and recent blood tests — are compiled and organised. Records in Indonesian or Bahasa should be accompanied by an English summary where possible. ChinaMed Waypoint can assist with organising and preparing these records for specialist review.
Step 2: Online MDT consultation
A Chinese haematology or oncology MDT reviews the records remotely and produces a written recommendation. This review clarifies whether treatment in China is clinically relevant for the specific case — and if so, which approach, which centre, and what the realistic process and timeline would be. No travel is required at this stage, and no commitment to proceed is implied by requesting a review.
Step 3: Decision and logistics
Based on the MDT recommendation, the family and their local oncology team decide whether to proceed. Only if the MDT confirms clinical relevance does the question of travel, logistics, and cost planning become the next priority. This sequencing — remote review first, travel second — avoids families incurring unnecessary costs and disruption before the clinical case has been properly evaluated.
For Indonesian families considering CAR-T therapy specifically, the CAR-T and cell therapy resource hub provides detailed information on the full treatment process, eligibility criteria, approved products, and cost framework for international patients.
Supportive Care During Treatment in China
For Indonesian patients undergoing intensive treatment in China — whether CAR-T therapy, bone marrow transplant, or prolonged chemotherapy — the treatment period itself can be physically and emotionally demanding, particularly for families far from home. Chinese oncology centres may incorporate integrative supportive care approaches alongside standard disease-directed treatment, including traditional Chinese medicine (TCM), acupuncture for fatigue and symptom management, nutritional support, and rest and recovery planning.
These integrative approaches are used as complementary care alongside — not instead of — chemotherapy, transplant, or CAR-T therapy. For families preparing for an extended stay in China, having access to structured supportive care can make a meaningful difference in overall wellbeing during the treatment period. See the Traditional Chinese Medicine and supportive care resources for more context on what integrative care during cancer treatment in China may involve.
Related Guides
CAR-T and Cell Therapy in China
The full CAR-T resource hub — approved products, eligibility, the treatment process, and how international patients access CAR-T at Chinese hospitals.
Haploidentical Transplant in China: When There Is No Matched Donor
The Beijing Protocol, parent donor options, and donor shortage pathways — for patients whose registry search has failed or is unlikely to succeed.
Why International Families Consider China for Complex Blood Disorders
The five clinical situations — including donor shortage, CAR-T access, and rare paediatric disease — that lead families from outside China to seek specialist care there.
Frequently Asked Questions
How much does CAR-T therapy cost in China for international patients?
CAR-T therapy in China is typically priced significantly lower than equivalent treatment in the United States or Western Europe. Product costs generally range from approximately USD 100,000–200,000, compared to USD 400,000–500,000 or more in the US. For families planning out-of-pocket treatment, this difference is material. Total costs should also account for hospitalisation, lymphodepleting conditioning chemotherapy, post-infusion monitoring, and accommodation — not the product price alone.
Full guide: CAR-T therapy costs in China for international patients →Why do Indonesian patients have difficulty finding a matched bone marrow donor?
International stem cell donor registries — including DKMS and NMDP/Be The Match — are predominantly composed of donors from European backgrounds. Indonesian patients searching for a matched unrelated donor (10/10 HLA match) face significantly lower match probabilities compared to patients of European descent. For families in this situation, haploidentical transplant using a biological parent as donor is an established alternative that does not depend on registry availability.
Does BPJS Kesehatan cover treatment in China?
BPJS Kesehatan, Indonesia's national health insurance programme, does not cover treatment received outside Indonesia. Indonesian patients considering treatment in China should plan for out-of-pocket costs, or confirm any private insurance coverage in advance. Families should request written confirmation of overseas coverage from their insurer before making financial commitments.
How long does treatment in China typically take for Indonesian patients?
The duration depends on the treatment type. A structured second opinion (online MDT) requires no travel and typically takes one to two weeks from records submission. CAR-T therapy involves a first trip of approximately two to three weeks for assessment and T-cell collection, followed by four to six weeks of manufacturing (during which patients may return home), and a second trip of four to six weeks for infusion and monitoring. Bone marrow transplant requires a continuous in-country stay of approximately three to five months, including post-transplant monitoring.
What is the first step for an Indonesian family wanting treatment or a second opinion in China?
The process begins with records — not travel. An online MDT consultation allows Chinese specialists to review the patient's case remotely and provide a recommendation before any decision about travel is made. This review typically requires existing medical records, pathology reports, imaging, and blood results. No commitment to treatment or travel is required at this stage.
Medical disclaimer
ChinaMed Waypoint is a coordination service, not a medical provider. Nothing in this article constitutes medical advice. All treatment decisions — including whether to pursue treatment in China, which institution to approach, and which approach is appropriate — must be made in consultation with qualified oncologists, haematologists, or transplant physicians who have reviewed the patient's complete clinical records and current health status.
Considering treatment in China from Indonesia?
An online MDT consultation with a Chinese specialist team reviews your case remotely and gives a concrete recommendation — before any travel decision is made. No commitment required to get started.
Request a case reviewFor CAR-T, donor shortage, paediatric blood disorders, and complex oncology cases — the process begins with records, not travel.